The COVID‐19 Pandemic and Its Influence on Patients With Myotonic Dystrophy Type 1: Lessons Learned
Brain and Behavior · 2024
DOI: 10.1002/brb3.70162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2024. Verfasst von Vera E A Kleinveld und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Myotonic Dystrophy, COVID-19. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Myotonic dystrophy type 1 (DM1) patients might represent a high‐risk population for severe COVID‐19 disease, as cardiopulmonary symptoms are part of the clinical spectrum of DM1. The COVID‐19 pandemic may have impacted DM1 patients. We aimed to determine the effect of the COVID‐19 pandemic on DM1 patients to guide management strategies in possible future pandemics.
Methods
Data on the presence of a COVID‐19 infection were retrieved from 195 DM1 patients in the MYODRAFT database. Between August 12 and October 4, 2021, 82 patients and proxies filled out a questionnaire on COVID‐19 symptoms, well‐being, and organization of care. Data were compared to prepandemic data.
Results
A total of 18 patients had COVID‐19 (13 confirmed, 5 probable infections). The prevalence of COVID‐19 in our cohort was 9.2%, which was lower than in the Dutch population (11.5%). Four patients (22.2%) were hospitalized due to a COVID‐19 infection, which was higher than in the Dutch population (3.6%). Two infected patients died. A high rate of canceled appointments was reported. Patients reported no change in physical functioning during the pandemic, whereas proxies reported a deterioration in mental and physical well‐being of patients.
Conclusions
The prevalence of COVID‐19 infections was not higher in DM1 patients than in the general population, but DM1 patients are more susceptible to complicated disease when infected. Longitudinal data on patient‐reported physical functioning suggest that the COVID‐19 pandemic and the pandemic management strategies implemented did not influence the course of disease in DM1 patients, and similar strategies can be re‐used in comparable situations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Neurology, School of Mental Health and Neuroscience, Maastricht University Medical Centre+, Maastricht, the Netherlands.
ORCID-Profile: Vera E A Kleinveld
Zitieren
APA
Kleinveld, V. E. A., Bruijnes, J. E., Labrecque, S., Jeurissen-Bekkering, D. E. G., Faber, C. G., & Horlings, C. G. C. (2024). The COVID‐19 Pandemic and Its Influence on Patients With Myotonic Dystrophy Type 1: Lessons Learned. Brain and Behavior. https://doi.org/10.1002/brb3.70162
Vancouver
Kleinveld VEA, Bruijnes JE, Labrecque S, Jeurissen-Bekkering DEG, Faber CG, Horlings CGC. The COVID‐19 Pandemic and Its Influence on Patients With Myotonic Dystrophy Type 1: Lessons Learned. Brain and Behavior. 2024. doi:10.1002/brb3.70162
BibTeX
@article{Kleinveld2024,
author = {Kleinveld, Vera E A and Bruijnes, Johanna E and Labrecque, Samuel and Jeurissen-Bekkering, Danielle E G and Faber, Catharina G and Horlings, Corinne G C},
title = {The COVID‐19 Pandemic and Its Influence on Patients With Myotonic Dystrophy Type 1: Lessons Learned},
journal = {Brain and Behavior},
year = {2024},
doi = {10.1002/brb3.70162}
}
EUVIMED